%0 Journal Article
%T NF-¦ÊB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers
%A Chunhong Li
%A Hailing Lu
%A Hang Yin
%A Hongxia Zhang
%A Jing Hu
%A Li Cai
%A Mengru Cao
%A Shi Yan
%A Xiaoyuan Wang
%J Archive of "Cell Death & Disease".
%D 2018
%R 10.1038/s41419-018-0447-7
%X a IHC staining yielded scores ranging from 0 to 3, which are representative of the amount of EHD1 and CD133 in lung cancer specimens. A score of 0¨C1 represented low expression, and 2¨C3 represented high expression. b The percentages of patients with high expression (black bar) and low expression of EHD1 (grey bar) were assigned according to different responses to EGFR-TKI (responder, n£¿=£¿12; nonresponder, n£¿=£¿11). Numbers near bars represent the percentage of patients for each condition. *P£¿<£¿0.05. c Mean OS of patients with high levels of EHD1 (n£¿=£¿11, OS of 26 mo) and low levels of EHD1 (n£¿=£¿12, OS of 39 mo) taking EGFR-TKI treatment. Mean PFS of patients with high levels of EHD1 (n£¿=£¿11, PFS of 11 mo) and low levels of EHD1 (n£¿=£¿12, PFS of 30 mo) taking EGFR-TKI treatment. P£¿=£¿0.049. d Patients with high CD133 expression were accompanied by increased expression of EHD1 protein. The expression levels of EHD1 were classified into two groups according to the IHC scoring: low-expression group (score 0 and 1) and high-expression group (score 2 and 3). e EHD1 expression in human lung cancer cell lines. f The correlation between EHD1 expression and IC50 of erlotinib in human lung cancer cell line
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856828/